Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (Cancelled).

22. (Currently amended): An oral dosage form comprising a first composition and a second composition, wherein each composition comprises a drug compound, which is 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof, and a pharmaceutically acceptable carrier therefor,

wherein the first and second compositions are arranged to release the drug compound at differing release rates on administration such that the rate of release of the drug compound from the dosage form is substantially independent of pH;

and wherein said oral dosage form further comprises a third composition which is a non-permeable enteric coating layer, wherein said third composition comprises one or more openings extending substantially completely through the third composition.

23. (Previously presented): An oral dosage form according to claim 22, wherein the release rate of the drug compound from the first composition is substantially greater than the release rate of the drug compound from the second composition.

24. (Previously presented): An oral dosage form according to claim 22, wherein the first composition is an immediate release composition.

25. (Previously presented): An oral dosage form according to claim 22, wherein the second composition is a modified release composition.

26. (Previously presented): An oral dosage form according to claim 22, wherein the rate of release of the drug compound from at least one of the first composition and the second composition is a modified release.

Claims 27-29 (Cancelled).

30. (Previously presented): An oral dosage form according to claim 22, wherein the first composition is arranged to release substantially all of the drug compound in the stomach.

31. (Previously presented): An oral dosage form according to claim 22, wherein the second composition is arranged to release substantially all of the drug compound in the small intestine.

32. (Previously presented): An oral dosage form according to claim 22, which dosage form is arranged to release the drug compound such that the mean maximum plasma level concentration value of the drug is maintained substantially independent of food during use.

33. (Previously presented): An oral dosage form according to claim 22, which dosage form is arranged to release the drug compound such that the mean area under the plasma concentration versus time curve over the dosing interval at steady state is maintained substantially independent of food during use.

34. (Previously presented): An oral dosage form according to claim 22, which dosage form is arranged to release the drug compound so that both the mean maximum plasma level concentration and the mean area under the plasma concentration versus time curve over the dosing interval at steady state are maintained substantially independent of food during use.

35. (Currently amended): An oral dosage form according to claim 22, comprising,

(i) an erodable core, which core comprises the first composition and the second composition; and

(ii) an erodable, non-permeable enteric coating around said core, which coating comprises one or more openings extending substantially completely through said coating but not penetrating said core and communicating from the environment of use to said core,

wherein release of the drug compound from the erodable core occurs substantially through the one or more openings and through erosion of said erodable coating under pre-determined pH conditions.

36. (Previously presented): An oral dosage form according to claim 35, wherein the first composition is formulated to provide an immediate release of the drug compound on contact with aqueous media.

37. (Previously presented): An oral dosage form according to claim 35, wherein the second composition is formulated to provide a modified release of the drug compound on contact with aqueous media.

38. (Previously presented): An oral dosage form according to claim 22, wherein the dosage form is a tablet form.

39. (Previously presented): A process for preparing the oral dosage form according to claim 22, which process comprises at least the steps of:

(i) formulating the drug compound into the first composition; and

(ii) formulating the drug compound into the second composition;

whereby the first and second compositions are formulated to release drug at differing release rates on administration such that the rate of release of the drug compound from the dosage form is substantially independent of pH.

40. (Previously presented): A process for the preparation of the oral dosage form according to claim 35, which process comprises:

(a) formulating the erodable core comprising the drug compound and a pharmaceutically acceptable carrier therefor;

(b) coating the core with the erodable coating; and

(c) forming one or more openings in the coating, said openings extending substantially completely through said coating but not penetrating said core and communicating from the environment of use to said core.

Claim 41. (Cancelled)

42. (New): A method for the treatment of diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose in a human or non-human mammal, which method comprises administering the oral dosage form according to claim 22 to said human or non-human mammal.

43. (New): A method for the treatment of Alzheimer's Disease in a human or non-human mammal, which method comprises administering the oral dosage form according to claim 22 to said human or non-human mammal.

44. (New): A method for the treatment of atherosclerosis in a human or non-human mammal, which method comprises administering the oral dosage form according to claim 22 to said human or non-human mammal.